



Leader in AAV Gene Therapy

**Corporate Presentation** 

February 18, 2021

## **Forward-looking statements**

This presentation includes "forward-looking statements," within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements express a belief, expectation or intention and are generally accompanied by words that convey projected future events or outcomes such as "believe," "may," "will," "estimate," "continue," "anticipate," "assume," "design," "intend," "expect," "could," "plan," "potential," "predict," "seek," "should," "would" or by variations of such words or by similar expressions. The forward-looking statements include statements relating to, among other things, REGENXBIO's future operations, clinical trials, costs and cash flow. REGENXBIO has based these forward-looking statements on its current expectations and assumptions and analyses made by REGENXBIO in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors REGENXBIO believes are appropriate under the circumstances. However, whether actual results and developments will conform with REGENXBIO's expectations and predictions is subject to a number of risks and uncertainties, many of which are beyond the control of REGENXBIO. For a summary of certain of these risks and uncertainties, refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of REGENXBIO's Annual Report on Form 10-K for the year ended December 31, 2019 and comparable "risk factors" sections of REGENXBIO's Quarterly Reports on Form 10-Q and other filings, which have been filed with the U.S. Securities and Exchange Commission (SEC) and are available on the SEC's website at www.sec.gov. All of the forward-looking statements made in this presentation are expressly qualified by the cautionary statements contained or referred to herein. The actual results or developments anticipated may not be realized or, even if substantially realized, they may not have the expected consequences to or effects on REGENXBIO or its businesses or operations. Such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Readers are cautioned not to rely too heavily on the forward-looking statements contained in this presentation. These forward-looking statements speak only as of the date of this presentation. REGENXBIO does not undertake any obligation, and specifically declines any obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.



**REGENXBIO**: seeking to improve lives through the curative potential of gene therapy

Pipeline focused on **AAV-mediated antibody delivery** and **rare genetic diseases** with **multiple clinical trials in 2021** 

Proprietary NAV<sup>®</sup> Technology Platform includes exclusive *worldwide rights to over 100 AAV vectors,* including AAV7, AAV8, AAV9 and AAVrh10 1 FDA-approved product using the NAV Technology Platform, and multiple clinical stage programs

being developed by third-party licensees across a broad range of therapeutic areas

Management team are **experienced drug developers** and **leaders in gene therapy**  Industry leader in AAV manufacturing



# **REGENXBIO's internal pipeline**

Indication	Development Stage				Commercial Rights	
	Research	Preclinical	Phase I / II	Pivotal		
Retinal Disease wet AMD	RGX-314 Subre	tinal				
vet AMD	RGX-314 Supra	choroidal			Worldwide	
biabetic retinopathy	RGX-314 Supra	choroidal				
Add'I anti-VEGF treated conditions						
LN2 disease 🔺 🗙	RGX-381				Worldwide	
leurodegenerative Disease	RGX-121				Worldwide	
1PS I ▲★■	RGX-111				Worldwide	
LN2 disease 🔺 🕇	RGX-181				Worldwide	
auopathies and $\alpha$ -synucleinopathies					Promised antibody througenets Co-Commercialization	
euromuscular Disease MD	RGX-202				Worldwide	
iver-directed ereditary angioedema					Worldwide	
REGENXBIO"		ediated antiboc genic gene repla	ly delivery for ch cement	ronic diseases	<ul> <li>▲ Orphan Drug Designation</li> <li>★ Rare Pediatric Disease Designation</li> <li>■ Fast Track Designation</li> <li>4</li> </ul>	









# **RGX–314: Potential best-in-class, one-time gene therapy** for treatment of wet age-related macular degeneration (wet AMD)

#### **THE DISEASE**

- Blurring of central vision and progressive vision loss due to formation of leaky blood vessels in the eye
- VEGF inhibitors are standard of care to treat fluid and associated vision loss
- Frequency / uncomfortable administration of current anti-VEGF therapies affects compliance and ultimately efficacy
- >2 million patients estimated in U.S., Europe and Japan

### **RGX–314 PRODUCT CANDIDATE**



#### Mechanism of action

Reducing leaky blood vessel formation by giving retinal cells the ability to produce an anti-VEGF fab

#### **Routes of administration**

Subretinal (SR)

Suprachoroidal (SC)











# **RGX–314 for treatment of wet AMD: Current program status**

#### Phase I/IIa subretinal dose-escalation study on-going<sup>1</sup>

- RGX-314 generally well-tolerated across all doses
- Durable treatment effect observed with stable to improved BCVA and CRT in Cohorts 3-5
- Long-term, meaningful reductions in anti-VEGF burden in Cohorts 3-5

#### Subretinal pivotal program is active and expected to support BLA filing in 2024


- Recently completed End of Phase 2 meeting with FDA
- Pivotal program to enroll a total of approximately 700 patients
- First trial, ATMOSPHERE<sup>™</sup>, is active and enrolling
- Clear path for cGMP manufacturing process to support BLA, bridging study expected to initiate in H1 2021

#### Phase II suprachoroidal AAVIATE trial on-going

- Cohort 1 enrollment complete; Cohort 2 enrollment expected to begin in Q1 2021
- Interim data from Cohort 1 expected in Q3 2021
- RGX-314 well-tolerated with no evidence of inflammation<sup>2</sup>




# **RGX–314 subretinal Phase I/IIa clinical trial:** Mean BCVA over 2 years (Cohort 3) and 1.5 years (Cohorts 4&5)





Note: One patient in Cohort 5 discontinued the study prior to Week 22 visit. Another patient in Cohort 5 has missed the visits since Week 46 visit due to COVID-19. For this patient, missing visits were imputed using last observation carried forward (LOCF) through Week 74 visit. Six additional missing BCVA results were interpolated.


# **RGX–314 subretinal Phase I/IIa clinical trial:** Mean CRT over 2 years (Cohort 3) and 1.5 years (Cohorts 4&5)





Note: One patient in Cohort 5 discontinued the study prior to Week 22 visit. Another patient in Cohort 5 has missed the visits since Week 46 visit due to COVID-19. For this patient, missing visits were imputed using last observation carried forward (LOCF) through Week 74 visit. Nine additional missing CRT results were interpolated.


# **RGX–314 subretinal Phase I/IIa clinical trial:** Cohort 3—5 injections preand post-RGX-314





# **RGX–314 subretinal Phase I/IIa clinical trial:** Mean BCVA over 2 years (Cohort 3) and 1.5 years (Cohorts 4&5)


Patients with no anti-VEGF injections within 12 months of last visit





Note: One patient in Cohort 5 discontinued the study prior to Week 22 visit. Another patient in Cohort 5 has missed the visits since Week 46 visit due to COVID-19. For this patient, missing visits were imputed using last observation carried forward (LOCF) through Week 74 visit. Two additional missing BCVA results were interpolated.

# **RGX–314 subretinal Long-Term Follow-Up\* trial:** Mean BCVA over three years in Cohort 3





\* Subjects will roll over from the Phase I/IIa study to the Long-Term Follow-Up study to assess safety and efficacy up to five years after RGX-314 administration.

# **ATMOSPHERE<sup>™</sup> pivotal clinical trial: RGX-314 for wet AMD**



## Primary

 Non-inferiority in the mean change in BCVA for RGX– 314 compared with monthly ranibizumab injection at 1 year

## Secondary

- Safety and tolerability of RGX-314
- Effect of RGX–314 on vision and retinal anatomy
- Additional anti–VEGF injections post-RGX–314

### Subjects: approximately 300 total

#### Route of administration: Subretinal

**Sites**: Up to 60 leading retinal surgery centers across the United States




## **KEY INCLUSION CRITERIA**

- Male or female ≥ 50 to 89 years of age
- Previously treated wet AMD subjects requiring anti-VEGF therapy
- Documented response to anti–VEGF at trial entry (assessed by SD–OCT)
- Vision of 20/32 to 20/160
- Pseudophakic (status post cataract surgery)



# **ATMOSPHERE<sup>™</sup> pivotal trial design**

## Administration and follow-up timeline



A second pivotal trial is expected to be similar in design to ATMOSPHERE, planned to initiate in H2 2021



# **AAVIATE<sup>™</sup>** Phase II clinical trial: **RGX-314** for wet AMD



## Primary

 To evaluate the mean change in BCVA for RGX-314 compared with ranibizumab monthly injection at Week 40

### Secondary

- Safety and tolerability of RGX-314
- Change in central retinal thickness (CRT) as measured by Spectral Domain Optical Coherence Tomography (SD-OCT)
- Additional anti–VEGF injections post-RGX–314

#### Subjects: Up to 40 total (randomized 3:1)

**Route of administration:** Suprachoroidal using SCS Microinjector

**Sites**: Fifteen leading retinal surgery centers across the United States







## **KEY INCLUSION CRITERIA**

- Male or female ≥50 to 89 years of age
- Previously treated wet AMD subjects requiring no more than 10 anti–VEGF injections in the 12 months prior to trial entry
- Documented response to anti–VEGF at trial entry (assessed by SD–OCT)
- BCVA between ≤ 20/25 and ≥ 20/125 (≤ 83 and ≥ 44 Early Treatment Diabetic Retinopathy Study [ETDRS] letters) in the study eye

# **AAVIATE<sup>™</sup>** Phase II clinical trial design

Administration and follow-up timeline







<sup>1</sup> Dose escalation safety review to occur two weeks after final subject in Cohort 1 has been dosed SD-OCT = spectral domain optical coherence tomography



# RGX-314 for treatment of Diabetic Retinopathy (DR)

### THE DISEASE

- Leading cause of vision loss in adults between 24–75 years of age; average age of onset is 45-50 years of age
- As disease progresses from non-proliferative DR (NPDR) to proliferative DR (PDR), patients are at increased risk of developing vision threatening complications
- Vision threatening complications include diabetic macular edema (DME) and neovascularization that can lead to blindness
- Approximately 8 million patients estimated in United States alone



### **RGX–314 PRODUCT CANDIDATE**



#### **Mechanism of action**

Reducing leaky blood vessel formation by giving retinal cells the ability to produce continuous anti-VEGF fab

#### **Route of administration**

Suprachoroidal



# **ALTITUDE<sup>™</sup>** Phase II clinical trial in DR



## Primary

 Evaluate proportion of patients with ≥2 step improvement in severity on the Diabetic Retinopathy Severity Scale (DRSS) at 48 weeks

### Secondary

- Safety and tolerability of RGX-314
- Development of DR-related ocular complications
- Need for additional standard of care interventions

#### Subjects: Up to 40 total (randomized 3:1)

**Route of administration:** Suprachoroidal using SCS Microinjector

**Sites**: Fifteen leading retinal surgery centers across the United States




## **KEY INCLUSION CRITERIA**


- Male or female ≥ 25 to 89 years of age with DR secondary to diabetes mellitus Type 1 or Type 2
- Moderately severe NPDR, severe NPDR, or Mild PDR
- No active DME, CST < 320 μm</li>
- Vision of 20/40 or better (≥ 69 Early Treatment Diabetic Retinopathy Study [ETDRS] letters) in the study eye



# **ALTITUDE<sup>™</sup>** Phase II clinical trial design

## Administration and follow-up timeline









# RGX-202 for treatment of Duchenne Muscular Dystrophy (DMD)

### THE DISEASE

- DMD is caused by mutations in the DMD gene which encodes for dystrophin, a protein involved in muscle cell structure and signaling pathways
- Without dystrophin, muscles throughout the body degenerate and become weak, eventually leading to loss of movement and independence, required support for breathing, cardiomyopathy and premature death
- Affects 1 in 3,500 to 5,000 male births worldwide

### **RGX–202 PRODUCT CANDIDATE**



#### **Mechanism of action**

Delivers transgene that encodes for novel microdystrophin which includes extended coding region of the C-Terminal Domain


#### **Route of administration**

#### Intravenous




# RGX-202 is designed to retain key elements of full-length dystrophin

# **CT** Domain has been shown to recruit several key proteins to the muscle cell membrane (sarcolemma) including Syntrophin and Dystrobrevin, Neuronal nitric oxide synthase and other proteins<sup>1</sup>



Presence of CT Domain in microdystrophin significantly improved the muscle resistance to lengthening contraction—induced muscle damage in DMD<sup>mdx</sup> mice<sup>2</sup>






<sup>1</sup> Allen et al, Physiological Review, 2016

<sup>2</sup> Koo et al, *Human Gene* Therapy, 2011

Syn: Syntrophin; Dbr: Dystrobrevin; CR: Cystein rich domain; nNOS: Neuronal nitric oxide synthase; DG: Dystroglycan; H: hinge; R: repeat


# **RGX-202 program has several features that provide potential benefits**




LEGENXBIO® <sup>1</sup> Koo et al, *k* <sup>2</sup> Faust, et al <sup>3</sup> Le Guiner, <sup>4</sup> Mack, et al <sup>5</sup> Shieh, et al

<sup>1</sup> Koo et al, Human Gene Therapy, 2011
 <sup>2</sup> Just, et al. Journal of Clinical Investigation, 2013
 <sup>2</sup> Le Guiner, et al. Nature Communications, 2017
 <sup>4</sup> Mack, et al. Molecular Therapy, 2017
 <sup>5</sup> Shieh, et al. ASGCT 2019


## **RGX-202** Proof of concept in DMD<sup>mdx</sup> mouse model




Histological evidence that RGX-202 recruits key proteins to DAPC



Significant strength and force improvements observed in DMD<sup>mdx</sup> mice treated with RGX-202



Mouse Grip Strength (In-Life)



#### **Ex Vivo Force Measurements**

500

300

200


100

BL10 vehicle

notvehicle

**ก**ับ 400

Maximal Force







## **REGENXBIO's neurodegenerative disease franchise**

### RGX-121 for MPS II

### RGX–111 for MPS I

- Reduced ability to process glycosaminoglycans (GAGs), leading to neurodegeneration and early death
- X-linked recessive disease

Disease

nations

- Available treatment is inadequate to treat neurodegeneration
- Approximately 500 1,000 patients born annually worldwide

- Reduced ability to process GAGs, leading to neurodegeneration and early death
- Autosomal recessive disease
- Available treatment is inadequate to treat neurodegeneration; stem cell transplant partially effective
- Approximately 500 1,000 patients born annually worldwide

## RGX–181 for CLN2 disease

- Reduced ability to process cellular waste peptides, leading to seizures, vision loss, neurodegeneration and early death
- Autosomal recessive disease
- Available treatment requires frequent ICV infusions of ERT, shown to stabilize some but not all disease manifestations
- Approximately 500 patients born annually worldwide

#### ΔΔV9 ΔΔV9 ΔΔV9 Vecto **IDS** gene replacement **IDUA** gene replacement **TPP1** gene replacement Gene Intracisternal Intracisterna Intracisterna Admin Orphan Drug Designation Orphan Drug Designation Orphan Drug Designation Desig Rare Pediatric Disease Designation **Rare Pediatric Disease Designation** \* Rare Pediatric Disease Designation

**Fast Track Designation** 

Fast Track Designation



# RGX–121 Phase I/II clinical trial in MPS II



### Primary

 To determine the safety and tolerability of RGX–121 in severe MPS II subjects who have or are at high risk of developing neurocognitive deficits

#### Secondary

- Effect of RGX–121 on biomarkers of I2S activity in CSF, serum and urine
- Effect of RGX–121 on neurocognitive deficits

#### Subjects: Approximately 12 patients

**Sites**: Leading U.S. and international lysosomal storage disease centers




#### **Key inclusion criteria**


- Male subjects ≥4 months to <5 years of age</p>
- Meeting one of the following criteria:
  - Diagnosis of MPS II and a score ≤77 on neurocognitive testing
  - Diagnosis of MPS II and a decline of ≥1 standard deviation on consecutive intelligent quotient testing
  - Having a relative diagnosed with severe MPS II who has the same IDS mutation as the subject
  - Having documented mutation(s) in IDS that is known to result in a neuronopathic phenotype
- No contraindications for intracisternal or intracerebroventricular injection and immunosuppressive therapy



# RGX-121 Phase I/II clinical trial: Administration and dose escalation

## Administration and follow-up timeline





#### Dosing in Cohort 3 expected to begin in Q1 2021




<sup>1</sup>Safety review to occur eight weeks after final subject in Cohort 1 has been dosed and after first three subjects in Cohort 2 have been dosed


# **RGX–121 Phase I/II clinical trial:** Safety update and data summary from Cohorts 1 and 2<sup>1</sup>

- Well-tolerated following one-time RGX-121 administration (n=8)
  - No drug-related Serious Adverse Events
- Biomarkers and measures of neurodevelopmental function indicate CNS activity following RGX-121 administration
  - Consistent reductions in CSF biomarkers up to 2 years after RGX-121 administration
  - Continued cognitive development and skill acquisition observed
- **•** Evidence of systemic enzyme expression and biomarker activity
  - Increased plasma enzyme levels
  - Rapid urine biomarker reductions observed in ERT<sup>2</sup>-naïve patients
  - Reduced liver and spleen volumes in one ERT-naïve patient



# **RGX–121 Phase I/II clinical trial:** Consistent reductions in CSF biomarkers up to 2 years after RGX-121 administration






Median change from baseline: -44.2% at Week 8; -39.2% at last timepoint available

EGENXBIO

# **RGX–121 Phase I/II clinical trial:** Continued cognitive development and skill acquisition observed in Cohorts 1 and 2 in patients with >6 months of follow-up

#### **Bayley Scales of Infant and Toddler Development, 3rd Edition (BSID-III)**




- Patients 1, 3 and 5 demonstrated continued cognitive development within a normal range
- Patients 2 and 4 entered the study with significant delay in neurocognitive development at baseline

Patient 2 has continued cognitive development

Patient 4 continued to acquire expressive and receptive language skills




# **RGX–121 Phase I/II clinical trial:** Evidence of systemic enzyme activity in Cohorts 1 and 2





# **RGX–121 Phase I/II clinical trial:** Urine biomarker reductions in Cohorts 1 and 2



# **RGX–111** Phase I/II clinical trial in MPS I



### Primary

 To determine the safety and tolerability of RGX–111 in MPS I subjects with neurocognitive deficits

#### Secondary

- Effect of RGX–111 on biomarkers of IDUA activity in CSF, serum and urine
- Effect of RGX–111 on neurocognitive deficits

#### Subjects: Up to 5 total

**Sites**: Leading U.S. and lysosomal storage disease centers







#### **Key inclusion criteria**

- Male or female ≥ 4 months of age
- Documented evidence of CNS involvement due to MPS I or documented diagnosis of MPS I
  - A score of ≥1 standard deviation below mean on intelligent quotient testing or in one domain of neuropsychological function
  - A decline of ≥1 standard deviation on sequential testing
  - Having documented biallelic mutation in IDUA predictive of severe MPS I or a relative diagnosed with severe MPS I
- No contraindications for intracisternal or intracerebroventricular injection or immunosuppressive therapy

# RGX-111 Phase I/II clinical trial: Administration and dose escalation

## Administration and follow-up timeline











## **REGENXBIO** | Industry leader in AAV production and manufacturing Deep in-house knowledge of vector characterization and strength in technical operations


3,000 ft<sup>2</sup> in-house GLP pilot plant with 3 X 200L bioreactor capacity
18,000 ft<sup>2</sup> of fully-operational advanced manufacturing and analytics lab space
30+ batches of cGMP bulk drug substance product covering multiple programs



Flexible, large-scale cGMP capacity



Candidate selection to clinical material in 12 months





Integrated process optimization to enable scale and quality



Analytical capabilities to ensure quality for patients



ZGZNXBIO

#### Key highlights of REGENXBIO's new headquarters

- Corporate, research and manufacturing headquarters to open in H1 2021
- cGMP manufacturing facility expected to be operational in H1 2022; will enable production at bioreactor scales up to 2,000L
- Integrated approach will allow for more efficient development and manufacturing of product candidates



# REGENXBIO's NAV Technology Platform has been widely adopted

Multiple clinical stage programs being developed by NAV Technology Licensees across a broad range of therapeutic areas

	Research		Preclinical		Phase I / II		Phase III / App	oroved
	Indication	Licensee	Indication	Licensee	Indication	Licensee	Indication	Licensee
Liver / hematologic	Undisclosed	ultrageny			Hemophilia A	Takeda		
					Hemophilia A			
					OTC Deficiency			
					GSDIa			
					Wilson Disease			
Central nervous system	CDKL5 Deficiency	ultrageny	Rett Syndrome	U NOVARTIS	SMA Type II / III	<b>U</b> NOVARTIS	SMA Type I*	Zolgensma®
	Undisclosed	Prevail	ALS SOD1	U NOVARTIS	Parkinson's w/ GBA & Neuronopathic Gauch		MPS IIIA	LYSŒENE § s <u>arepit</u> a
	TLE		Friedreich's ataxia	Pfizer	MPS IIIA	ESTEVE		
			FTD-GRN	Prevail				
Cen			Synucleinopathies (GBA + α-Syn RNAi)	Prevail THERAPEUTICS				-
Cardiac / skeletal	muscle				Danon Disease	pharma	XLMTM	🔭 astellas –
Cardiac skeleta	E				Pompe Disease	Astellas		
$\checkmark$	$\rightarrow$						/	

ZEGENXBID



# Team and Conclusion



# The **REGENXBIO** team

Name	Position	Prior Affiliations		
Ken Mills	President, CEO & Co-Founder; Director	FOXKISER		
Olivier Danos, Ph.D.	SVP and Chief Scientific Officer	Biogen	cnrs	
Vit Vasista	SVP and Chief Financial Officer	PRTM		
Steve Pakola, M.D.	SVP and Chief Medical Officer	aerpio		
Curran Simpson	SVP, Chief Operations and Technology Officer	gsk	Human Genome Sciences	
Ram Palanki, Pharm.D.	SVP, Commercial Strategy and Operations	Santen	<b>Genentech</b> A Member of the Roche Group	
Patrick Christmas, J.D.	SVP, Chief Legal Officer	Lumara Health	WELLSTAT THERAPEUTICS	
Laura Coruzzi, Ph.D., J.D.	SVP, Intellectual Property	J	DAY.	
Shiva Fritsch	SVP, Chief People Officer	NOVAVAX	Human Genome Sciences	
REGENXBI	®		38	

## The NAV Technology Platform is based on a broad and deep IP portfolio

# Exclusive rights to more than **100 patents** and **patent applications worldwide**

- AAV7, AAV8, AAV9, AAVrh10
- Over 100 other novel AAV sequences
- Sequences that are at least 95% identical to these capsids

## Key features of REGENXBIO's NAV Technology Platform

- Broad and novel tissue selectivity
- Improved manufacturability
- Higher gene transfer

EG/EN)

Longer-term gene expression

The NEW ENGLAND JOURNAL of MEDICINE

Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B

## Benchard The NEW ENGLAND JOURNAL of MEDICINE

Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy

39

# **Financial results and guidance**

## 2020 YTD financials as of 9/30/20 (mm)

Revenue:	\$133.1
R&D expense:	\$119.1
G&A expense:	\$46.2
Net loss:	\$65.0
Basic share count:	37.4

### Program guidance and anticipated milestones

## **Recent financial highlights**

Expected to report between \$515 - \$530 million in cash<sup>1</sup> as of December 31, 2020<sup>2</sup>

YTD Q3 2020 revenues include an **\$80.0 million milestone payment** recognized upon the achievement of \$1.0 billion in cumulative net sales of Zolgensma

Completed partial monetization of Zolgensma royalty stream in Q4 2020 for gross upfront payment of \$200 million

**Gross proceeds of over \$230 million** raised from underwritten public offering completed in January 2021<sup>3</sup>


RGX-314	Subretinal wet AMD: ATMOSPHERE <sup>™</sup> to begin dosing patients in Q1 2021 Suprachoroidal wet AMD: Interim data from AAVIATE <sup>™</sup> Cohort 1 expected in Q3 2021 Suprachoroidal DR: Initial data from ALTITUDE <sup>™</sup> expected in 2021
RGX-202	IND submission in mid-2021
RGX-121	Cohort 3 of Phase I/II trial to begin enrollment in Q1 2021
RGX-111	First patient recently dosed in Phase I/II trial
RGX-181	IND submission in Q1 2021
RGX-381	IND, or foreign equivalent, submission in H1 2021

## **Financial guidance:**

REGENXBIO expects to report that as of December 31, 2020, it had between \$515 and \$530 million in cash,<sup>1, 2</sup> which it believes is sufficient to fund its operations, including the completion of its internal manufacturing capabilities and clinical advancement of its product candidates, until late 2022.



 <sup>1</sup> Cash includes cash, cash equivalents and marketable securities for the purposes of this presentation
 <sup>2</sup> Actual results may differ materially from these preliminary estimates. Please see "Preliminary Financial Information" in REGENXBIO's press release dated January 5, 2021 for further information.
 <sup>3</sup> Includes full exercise of underwriters' option to purchase additional shares. Please see REGENXBIO's press release dated January 12, 2021 for further information.



# **Thank You**

